This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for ReFacto AF® (moroctocog alfa) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

A guide on how to administer and reconstitute ReFacto AF using the FuseNGo and R2 devices.

Adminstration1

ReFacto AF is administered by intravenous infusion over several minutes after reconstitution of the lyophilised powder for injection with sodium chloride 9 mg/ml (0.9%) solution for injection (provided). The rate of administration should be determined by the patient's comfort level.

Reconstitution​​​​​​​

ReFacto AF can be reconstituted and administered using our R2 or FuseNGo device.

We’ve created the ‘ReFacto AF R2 infusion mat’ and ‘ReFacto AF FuseNGo infusion mat’ as support materials for your patients. They provide a detailed and visual step-by-step guide on how to use each device. 

In addition, we have also produced an informative leaflet for patients using the FuseNGo device.

You can download these materials for your patients by following the link below, or alternatively get in contact with the Pfizer Haemophilia team to request printed versions.

Download materials for your patients

Click here

Explore more

Find out about ReFacto AF dosing for on-demand treatment and prophylaxis

Click here

Find out about how ReFacto AF allows for flexible dosing

Click here
References
  1. ReFacto AF (moroctocog alfa) Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/6558/smpc
PP-REF-GBR-0200. March 2021

Contact Pfizer

Speak to a member of the Pfizer Haemophilia team.

Click here

Find out about ReFacto AF efficacy 

Click here

Find out about the ReFacto AF Laboratory Standard

How to order

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No